{"name":"fan li","slug":"fan-li","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AK112 with SCRT","genericName":"AK112 with SCRT","slug":"ak112-with-scrt","indication":"Unknown","status":"phase_2"},{"name":"Terelizumab","genericName":"Terelizumab","slug":"terelizumab","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AK112 with SCRT and CapeOX","genericName":"AK112 with SCRT and CapeOX","slug":"ak112-with-scrt-and-capeox","indication":"Advanced or metastatic solid tumors (in combination with capecitabine and oxaliplatin)","status":"phase_2"}]}],"pipeline":[{"name":"AK112 with SCRT and CapeOX","genericName":"AK112 with SCRT and CapeOX","slug":"ak112-with-scrt-and-capeox","phase":"phase_2","mechanism":"AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors.","indications":["Advanced or metastatic solid tumors (in combination with capecitabine and oxaliplatin)"],"catalyst":""},{"name":"AK112 with SCRT","genericName":"AK112 with SCRT","slug":"ak112-with-scrt","phase":"phase_2","mechanism":"AK112 with SCRT is a small molecule that targets the molecular target to exert its therapeutic effect.","indications":["Unknown"],"catalyst":""},{"name":"Terelizumab","genericName":"Terelizumab","slug":"terelizumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQZzdOZmdJLUpNdEsyZl9mS1V2a0tYUjBSNTlhaG9Fbllucng5YWVNSEJqX21OYU9QOG1LNGY4TVlHWi1TYU1scVdla283QzJyZVp1REJQRG4xOE4xTVp5TUkzeGl3MXhZTHVzVGhYeUd4ZEFyWVY4Z0xpcy1teXR6SlZUS0tFazlNS29GeUdsVkthcm00RTln?oc=5","date":"2024-12-13","type":"pipeline","source":"Fierce Biotech","summary":"AI firm Xaira powers up C-suite with pharma vet—Chutes & Ladders - Fierce Biotech","headline":"AI firm Xaira powers up C-suite with pharma vet—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPZ2Z5aEVyX2xIS2YyTFZtWU9paWZWaWYzd1hUdm03LXIxM0tyZTh0cWo3THVLRUFJUzZSZ2llY2tFQXJlWkVhXzIzS0ZybVZMdWRiZmh6OTdxRWJjaV9ZQmxNYXR6YkFYMjdkN2xHODd4X3hkYS15V0JIMHJoS2ZuY0t3RVNMMUIxajl5OFJzdFpjVXNxYm81aEFqZ3NMUTh1N2lZ?oc=5","date":"2024-10-15","type":"trial","source":"Freshfields Risk & Compliance","summary":"Beijing FTZ publishes rules for ‘important data’, Richard Bird, Fan Li - Freshfields Risk & Compliance","headline":"Beijing FTZ publishes rules for ‘important data’, Richard Bird, Fan Li - Freshfields Risk & Compliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5rZHBUVUdheHFibDlHV2wyMjNtalNvbjJIc2JsQnhQb1JYSHpSSFNsaWhvMnY2SUFCMXRRZm9JYTJ0eWo2cnI1djBQdEV2bUJyeFdTSW9LQ19Ia3JuRzFR?oc=5","date":"2024-05-10","type":"trial","source":"nature.com","summary":"Pharmaceutical treatment status of patients with COPD in the community based on medical Internet of Things: a real-world study - nature.com","headline":"Pharmaceutical treatment status of patients with COPD in the community based on medical Internet of Things: a real-world","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8ycjl6anpycVVlRlA0ajh6TEpVUjRoTXR4X3hfcXBwX3MzWTRreUVtYUwxU016TTlYd1lHYVpVWkNlQ2UwM2ZKWS1feGxvSENSbEI2YlNFTEhxQkZ5a0d1eGpMOGNraU5OS1VCUGQwVzBDZWphcGZWZnZibm1JX28?oc=5","date":"2023-12-20","type":"pipeline","source":"Oakland University","summary":"At the Cutting Edge - Oakland University","headline":"At the Cutting Edge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTFBNWGxDanJGby1CQmV4em9iQXowWXpQMHRCX2xCaFdjbW5aYmRQdzd0V0tKNWlHOFJobVJkNllaMzVMckMtMEhIbW5zUmdPbzQ?oc=5","date":"2023-06-08","type":"pipeline","source":"Sixth Tone","summary":"China Wakes Up to Danger From Illegal Lab Monkey Trade - Sixth Tone","headline":"China Wakes Up to Danger From Illegal Lab Monkey Trade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNb3hnOHhWVHZlYU5qUUd0UHJkaUpMWk5POWYyS3R3Q2txSktRSWhfWnJ6ak9mV2JjdEFUbHFRdzR0ZC1vMzYxLUxxRGpzSHFleVZJWm8wb3REV3loR0Z2Vnppd09nU3hkclY0YTZPSkN4U0s4N0NxeUx4dWpSX0hwZmxhVl9JSFFkV2wzOEtEVUJKUlVL?oc=5","date":"2023-05-23","type":"pipeline","source":"Frontiers","summary":"Beyond cellulose: pharmaceutical potential for bioactive plant polysaccharides in treating disease and gut dysbiosis - Frontiers","headline":"Beyond cellulose: pharmaceutical potential for bioactive plant polysaccharides in treating disease and gut dysbiosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1tV3ltajBDSGVoY1V3S0dpX3ExQjlQYk5vbjF3TFpsQ19aeV9uektHckZvaFo3RXIyQ1NBMldlUXVmVE9yTHFzMVU5V1pJT2xjSzB1OVBVaFVHb0xiakJFRFRsdzdOWW1iVk5kSm1lUQ?oc=5","date":"2020-05-15","type":"pipeline","source":"Wiley Online Library","summary":"Synergistic Dual‐Additive Electrolyte Enables Practical Lithium‐Metal Batteries - Wiley Online Library","headline":"Synergistic Dual‐Additive Electrolyte Enables Practical Lithium‐Metal Batteries","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}